- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00255593
Safety and Efficacy Study of Rituximab in Renal Transplantation
November 29, 2007 updated by: Karolinska University Hospital
A Prospective, Randomised, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Rituximab as Induction Therapy Together With Tacrolimus, Mycophenolate Mofetil and Steroids for Patients Undergoing Renal Transplantation
Current strategies for the medical management of transplant patients are largely focused on the prevention and treatment of T-lymphocyte mediated processes.
However there is an increasing evidence to suggest that B-lymphocytes have a role in the otherwise classic T-cell mediated rejection of transplants by there ability to act as antigen presenting cells and T-cell activators.
Thus there is a significant medical need for effective therapies targeting B cells of transplant patients.One such potential therapy would be to use rituximab, a monoclonal antibody against B-cells in all renal transplant patients.
In the present study the efficacy and safety of prophylactic rituximab is studied.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
140
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Stockholm, Sweden, 141 86
- Transplantation Surgery, Karolinska University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients aged 18 years or above
- Recipients of first or second renal transplants
- Recipients of kidneys from living or cadaveric donors
- Single organ recipients (kidney only)
- Patients providing written informed consent
- Patients cooperative and able to complete all the assessment procedures
Exclusion Criteria:
- Patients receiving other immunosuppressive therapy within the preceding 28 days
- Recipients of HLA-identical sibling kidneys
- Patients with flow-PRA >50% within 6 months prior to enrolment
- Recent history of malignancy
- Active infection
- Pregnant or lactating females
- Women of childbearing potential not willing to use reliable form of contraception
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Composite endpoint of biopsyproven rejection, graft loss or death during the first 6 months following transplanation
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Renal function at 6 months
|
|
Incidence of infections
|
|
Incidence of rituximab-related adverse events
|
|
Incidence of malignancies
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Gunnar E Tydén, Professor, Karolinska Institutet
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2005
Study Completion (Actual)
October 1, 2007
Study Registration Dates
First Submitted
November 18, 2005
First Submitted That Met QC Criteria
November 18, 2005
First Posted (Estimate)
November 21, 2005
Study Record Updates
Last Update Posted (Estimate)
November 30, 2007
Last Update Submitted That Met QC Criteria
November 29, 2007
Last Verified
October 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Eudra CT: 2005-001231-29
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.